Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Akhil Sood MD AkhilSoodMD
3 years 1 month ago
Abstr #0078
Ogdie et al found that
- Pts seen by rheumatologists more likely receive bDMARDs or csDMARDs
- Opiates & non-Opiate pain medications were more commonly prescribed to pts seen by PCPs alone
@RheumNow #ACR22
https://t.co/uDcOc0Nn3Y https://t.co/FeAq21fiVs
Eric Dein ericdeinmd
3 years 1 month ago
Year in Review #ACR22
GLORIA
Low steroid usage: lower DAS28, reduced joint damage
BUT 24% increased adverse effects
@RheumNow https://t.co/vYTAhoQEqr
ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick rundown of what to expect!
Dr. John Cush RheumNow
3 years 1 month ago
We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/P41KybUuNw
sheila RHEUMarampa
3 years 1 month ago
Inspiring words from Dr. @cuttingforstone, "For these times, we must heed the call to adventure, find the tools & weapons never thought of before, have courage, have faith, tell our story, find our epiphanies bec this too shall pass..."
#ACR22 @RheumNow #RheumTwitter https://t.co/l3DPnIBxq6
TheDaoIndex KDAO2011
3 years 1 month ago
“The Stone Age did not end because we ran out of stones, it's because we found better technology.” – Dr. A. Verghese on how we need to be smarter about the practice medicine to accomplish more without being bogged down by logistics. #scribes @cuttingforstone @rheumnow #ACR22 https://t.co/20fP8cRRrv
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#0063 How can we improve adherence of #lupus patients to therapy? Dr Sun et al. showed reviewing prescription record in clinic and ~4min honest discussion on non-adherence improved uptake in 44% at next visit @RheumNow https://t.co/jGuK4Th1lg https://t.co/62u07jDNav
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#0343 Data from SLICC cohort showed non-adherence to hydroxychloroquine (detected by HCQ level) was associated with increased risk of flares, early damage and 5-yr deaths. It’s time to monitor level in patients who are not doing so well @RheumNow https://t.co/CdFIRcSYQD
Adela Castro AdelaCastro222
3 years 1 month ago
The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #AnkylosingSpondylitis. Check our NMA poster today. #ACR22 #SpA #medtwitter @TheBold_MD @cplch19 @UTSWRheum @ACRheum @RheumNow @DrCassySims https://t.co/vxa05r0GvS
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#0359 Is 2021 DORIS remission attainable in #lupus? Pooled analyses of Anifrolumab RCTs showed this was met in ~10% patients in treatment group vs 3% placebo. Faster and sustained too @Rheumnow https://t.co/5MY2O8i2gA https://t.co/PUeUY25JZl
Adela Castro AdelaCastro222
3 years 1 month ago
#ACR22 Raynaud’s:
💡Primary RP is the most common
💡Autoimmune RP is rare! Other causes more common: metabolic, trauma, vibration, Buergers.
💡NMA showed that both CCB and PDE5i reduced frequency and severity of symptoms
💡Supportive measures are cornerstone!
@ACRheum @RheumNow https://t.co/tb5FEmHJDz
Patricia Harkins DrTrishHarkins
3 years 1 month ago
“For the secret of the care of the patient is in caring for the patient”
- Francis W Peabody
What a poignant end to a fantastic key note speech by Dr Abraham Verghese!
#ACR22 @RheumNow https://t.co/R6Z1h8em7n
TheDaoIndex KDAO2011
3 years 1 month ago
"One more thing you need in a story-- Epiphany, where the soul of the commonest object seems radiant" - Dr. Verghese. His #epiphany occurred in the #HIV era helping a dying patient come to terms w/death; he discovered “The doctor can heal without curing.” #ACR22 @rheumnow https://t.co/Yh3SU4AMIZ
David Liew drdavidliew
3 years 1 month ago
GCA with visual symptoms:
do you hit the pulse iv methylpred button? Why?
260 pts from Lund 🇸🇪
no doubt some channelling, but:
IVMP no better and more steroid exposure/toxicity
This adds to existing doubts. Time to seriously question this practice?
ABST0459 #ACR22 @RheumNow https://t.co/nbQlhvoRQP
The management of RA patients with a history of cancer continues to be an area of concern. General recommendations are to treat patients with a history of solid organ cancer as no different to any other RA patient. Recently, the ORAL-Surveillance study demonstrated evidence of a greater risk of cancer with tofacitinib than with TNF inhibitors. In this setting, two posters both reassure and raise a new cause for concern.
Poster Hall